Advancing a High-Value
Therapeutic Pipeline.
Structured preclinical validation advancing Zegen-X5 toward IND-enabling studies and strategic biopharmaceutical partnership milestones.
Development Programs & Clinical Stages
Four targeted indications addressing acute, chronic, and emergency wound-healing deficits using tailored delivery modalities.
Diabetic Foot Ulcers (DFU)
Delivery Modality: Topical Gel
Targeted lead preclinical candidate for stalled chronic neuropathic and neuroischemic diabetic foot ulcers. Demonstrates 2X acceleration in closure rate at Day 10 in preclinical models.
Venous Leg Ulcers (VLU)
Delivery Modality: Matrix Sheet
Designed to work synergistically under multi-layer compression wraps for chronic venous insufficiency wounds.
Deep Partial-Thickness Burns & Trauma
Delivery Modality: Topical Spray
Rapid field deployment candidate for thermal burn debridement and trauma wound triage without requiring cold chain logistics.
Surgical Incision Dehiscence & High-Tension Closures
Delivery Modality: Extended-Release Candidate
Designed to enhance tissue tensile strength and prevent surgical breakdown in high-risk incisions.
Capital Efficiency & Targeted Use of Funds
Structured to maximize value inflection points across preclinical validation and IND-enabling milestones.
DFU Preclinical & IND-Enabling
Completion of lead DFU preclinical efficacy, toxicology validation, and FDA IND-enabling studies.
Formulation & CMC Scale-Up
Porcine GLP safety validation and commercial-grade cGMP batch manufacturing readiness.
Pipeline Indication Expansion
Preclinical validation across expanded chronic ulcer and thermal burn indications.
Regulatory & G&A
Legal, patent prosecution, regulatory preparation, and general operating costs.
Partner With ZegeneX
Explore co-development collaborations, territory licensing rights, and institutional investment opportunities in our lead and pipeline assets.
Request Partnering Package & Data Room Access